Kwality Pharmaceuticals delivered exceptional financial results for the quarter ended March 2026, with consolidated net profit surging 74.60% to ₹25.30 crore compared to ₹14.49 crore in the corresponding quarter of the previous year. According to reports from Business Standard, the pharmaceutical company's sales revenue increased 35.81% to ₹157.11 crore during the quarter, up from ₹115.68 crore in Q4 FY2025. The company's operating profit margin (OPM) improved to 24.67% in Q4 FY2026, compared to 22.37% in the same quarter of the previous year. On a sequential basis, net profit increased 58.02% and revenue grew 27.27% over Q3 FY26, demonstrating strong quarter-on-quarter momentum.
For the complete financial year ended March 2026, Kwality Pharmaceuticals demonstrated sustained growth momentum with consolidated net profit rising 69.01% to ₹67.35 crore compared to ₹39.85 crore in FY2025. As reported by Business Standard, the company's annual sales revenue grew 35.89% to ₹503.08 crore in FY2026, up from ₹370.20 crore in the previous financial year. The company's profit before tax (PBT) increased 67% to ₹90.32 crore for the full year, while profit before depreciation and tax (PBDT) rose 52% to ₹110.13 crore. However, net cash used in operating activities stood at ₹16.59 crore in FY26 compared with positive operating cash flow of ₹52.72 crore in FY25, indicating some working capital challenges despite strong profitability.
The company's profit before tax (PBT) for Q4 FY2026 stood at ₹31.67 crore, representing a significant increase from ₹19.07 crore in Q4 FY2025. According to the financial data reported by Business Standard, PBDT for the quarter rose 53% to ₹36.93 crore compared to ₹24.16 crore in the corresponding quarter of the previous year. EBITDA jumped 50.38% to ₹38.8 crore in the March quarter, compared with ₹25.8 crore a year earlier, with EBITDA margin improving to 24.6% from 22% in the corresponding period last year. The strong performance across all profitability metrics reflects the company's operational efficiency and market positioning in the pharmaceutical sector.
